Bernd Bokemeyer
Overview
Explore the profile of Bernd Bokemeyer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
1552
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bokemeyer B, Serdani-Neuhaus L, Sunwoldt J, Dunweber C, Schnaidt S, Schuppan D
Therap Adv Gastroenterol
. 2025 Feb;
18:17562848251314803.
PMID: 39906416
Background: Coeliac disease (CeD) is a chronic immune-mediated disease triggered by exposure to dietary gluten in genetically predisposed individuals. The burden of CeD on patients and the healthcare system remains...
2.
Schulz F, Foldenauer A, Weidmann L, Thomann A, Tal A, Plachta-Danielzik S, et al.
J Clin Med
. 2025 Jan;
13(24.
PMID: 39768729
Inflammatory bowel disease (IBD) remains an incurable illness. Patients with IBD show gender-specific differences in various aspects of the disease. There is still uncertainty about the causality of the differences....
3.
Al Sulais E, Louis E, Bokemeyer B, Gecse K, Parkes G, Parkes M, et al.
J Crohns Colitis
. 2024 Sep;
19(2).
PMID: 39243391
Background And Aims: Corticosteroids are widely used in managing inflammatory bowel disease (IBD). While adverse events (AEs) of corticosteroids are well recognized, current understanding of corticosteroid-related AE burden in IBD...
4.
Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignass A, Ehehalt R, et al.
Z Gastroenterol
. 2024 Aug;
62(8):1229-1318.
PMID: 39111333
No abstract available.
5.
Zhuleku E, Wirth D, Nissinen R, Bravata I, Ziavra D, Duva A, et al.
Therap Adv Gastroenterol
. 2024 Aug;
17:17562848241262288.
PMID: 39086989
Background: Biologic agents have demonstrated efficacy in treating ulcerative colitis (UC); however, treatment failure to tumor necrosis factor inhibitors (TNFi) is common in the real world. Data on preferential sequencing...
6.
Kruis W, Bokemeyer B, Jessen P, Hoesl M, Mross M, Morgenstern J, et al.
Inflamm Bowel Dis
. 2024 Apr;
31(3):677-685.
PMID: 38648264
Background And Aims: The course of Crohn's disease (CD) is highly variable. The Prospektive Evaluation eines Score zur Vorhersage eines milden Verlaufsbei neu diagnostizierten Morbus Crohn-Patienten in gastroenterologischen Fachpraxen (PROGNOS)...
7.
Bokemeyer B, Plachta-Danielzik S, Steiner I, Pohlschneider D, Urzica E, Hartmann P, et al.
Aliment Pharmacol Ther
. 2024 Mar;
59(9):1082-1095.
PMID: 38429885
Background: IBD was a randomised controlled trial assessing the efficacy of care provided by IBD nurse specialists in Germany in improving health-related quality of life (QoL) in IBD patients on...
8.
Bokemeyer B, Plachta-Danielzik S
Aliment Pharmacol Ther
. 2023 Nov;
59(1):142-143.
PMID: 37924219
No abstract available.
9.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Efken P, Mohl W, Hoffstadt M, et al.
Inflamm Bowel Dis
. 2023 Jul;
30(5):746-756.
PMID: 37523666
Background: The aim of this observational, real-world evidence, modified intention-to-treat (mITT) study based on prospectively collected data from the VEDOIBD registry was to compare the effectiveness of vedolizumab (VEDO) vs...
10.
Steiner I, Bokemeyer B, Stargardt T
Eur J Health Econ
. 2023 Jun;
25(3):539-548.
PMID: 37368061
Objective: Clinical studies commonly use disease-specific measures to assess patients' health-related quality of life. However, economic evaluation often requires preference-based utility index scores to calculate cost per quality-adjusted life-year (QALY)....